Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 5, 2003, Pages 357-403

  Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Amphotericin B; Doxorubicin; Paclitaxel; Pluronics ; Poly(ethylene glycol)

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BENZO[A]PYRENE; BENZOPORPHYRIN DERIVATIVE; CREMOPHOR; CYCLOSPORIN A; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; MACROGOL; NYSTATIN; PACLITAXEL; PHOTOSENSITIZING AGENT; PLURONIC P 123; PLURONICS; POLOXAMER; POLYCAPROLACTONE; POLYENE ANTIBIOTIC AGENT; POLYETHYLENE GLYCOL B POLYAMINO ACID; POLYETHYLENE GLYCOL B POLYESTER; POLYETHYLENE GLYCOL B POLYLYSINE CYCLOPHOSPHAMIDE DERIVATIVE; POLYETHYLENE GLYCOL DISTEAROYLPHOSPHATIDYLETHANOLAMINE; POLYMER; PROPOFOL; SP 1049C; UNCLASSIFIED DRUG;

ALOPECIA; ANAPHYLAXIS; ANOREXIA; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEVER; HEADACHE; HOST RESISTANCE; HUMAN; INJECTION PAIN; LETHARGY; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; MICELLE; MULTICENTER STUDY; MYALGIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; REVIEW; RIGOR; SOLID TUMOR; THERMODYNAMICS; VOMITING;

DRUG STABILITY; HUMANS; MICELLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLOXAMER; POLYETHYLENE GLYCOLS; SOLUBILITY; SURFACE-ACTIVE AGENTS; WATER;

EID: 1642541103     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20     Document Type: Review

References (129)

1. Henry CM. Special delivery. ACS J 2000; 78:49-65.
2. Jonkman-de Vries JD, Flora KP, Bult A, Beijnen JH. Pharmaceutical development of (investigational) anticancer agents for parenteral use-review. Drug Dev Ind Pharm 1996; 22:475-94.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-98.
4. Hodgson J. ADMET-turning chemicals into drugs. Nature Biotech 2001; 19:722-26.
5. Müller RH, Heinemann S. Emulsions for intravenous administration. I. Emulsions for nutrition and drug delivery. Pharm Ind 1993; 55:853-56.
6. Drummond D, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51:691-744.
7. Sinhababu AK, Thakker DR. Prodrugs of anticancer agents. Adv Drug Deliv Rev 1996; 19:241-73.
8. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev 1999; 99:3181-98.
9. Duncan R. The dawning era of polymer therapeutics. Nature Rev Drug Discov 2003; 2:347-60.
10. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev 2001; 53:247-64.
11. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46:149-68.
12. Schiffelers RM, Bakker-Woudenberg IAJM, Storm G. Localization of sterically stabilized liposomes at klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochim Biophys Acta Biomembranes 1999; 142:329-39.
13. Meerum Terwogt JMM, ten Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes IAM, Zurio MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH. Phase I clinical and pharmacokinetics study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001; 12:315-23.
14. Schoemaker NE, van Kesteren C, Rosing H, Jansen S, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia Porro M, Beijnen JH, Schllens JHM, ten Bokkel Huinink WW. A phase I and pharmacokinetics study of MAG-CPT, a water-soluble polymer conjugate of comptothecin. Br J Cancer 2002; 87:608-14.
15. Sabbatini P, Brown J, Aghajanian C, Hensley ML, Pezzulli S, O'Flaherty C, Funt S, Warner M, Mitchell P, Bolton MG, Spriggs D, Duggan B. A phase I/II study of PG-paclitaxel (CT-2103) in patients (PTS) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc Am Cancer Res 2002; 87.
16. Ochoa L, Tolcher A, Rizzo J, Schwartz G, Putnaik A, Hammond L, McCreery H, Denis L, Hidalgo M, Kwiatek J, McGuire J, Rowinsky E. A phase I study on PEG-camptothecin (PEG-CPT) in patients with advanced solid tumors: a novel formulation for an insoluble but active agent. Proc Am Cancer Res 2000; 19.
17. Yokoyama M. Block copolymers as drug carriers. Crit Rev Ther Drug Carrier Syst 1992; 9:213-48.
18. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Block copolymer micelles as vehicles for drug delivery. J Control Release 1993; 24:119-32.
19. Kwon GS. Diblock copolymer nanoparticles for drug delivery. Crit Rev Ther Drug Carrier Syst 1998; 15:481-512.
20. Alakhov VY, Kabanov AV. Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Expert Opin Invest Drugs 1998; 7:1453-73.
21. Allen C, Eisenberg A, Maysinger D. Copolymer drug carriers: conjugates, micelles and microspheres. STP Pharm Sci 1999; 9:139-51.
22. Jones MC, Leroux JC. Polymeric micelles-a new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999; 48:101-11.
23. Torchilin VA. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001; 73:137-72.
24. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47:113-31.
25. Chu B and Zhou Z. Physical chemistry of polyoxyalkylene block copolymer surfactants. In: Nace VM, editor. Nonionic Surfactants. New York: Dekker, 1996.
26. Riess G. Micellization of block copolymers. Prog Polym Sci 2003; 28:1107-70.
27. Tian M, Qin A, Ramireddy C, Webber SE, Munk P, Tuzar Z, Procháka K. Hybridization of block copolymer micelles. Langmuir 1993; 9:1741-48.
28. Wang Y, Balaji R, Quirk RP, Mattice WL. Detection of the rate of exchange of chains between micelles formed by diblock copolymers in aqueous solution. Polym Bull 1992; 28:333-38.
29. van Stam J, Creutz S, De Schryver FC, Jerome R. Tuning of the exchange dynamics between block copolymer micelles with temperature, cosolvents, and cosurfactants. Macromolecules 2000; 33:6388-95.
30. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82:189-212.
31. Pruitt JD, Husseini G, Rapoport N, Pitt WG. Stabilization of pluonic p-105 micelles with an interpenetrating network of N,N-diethylacrylamide. Macromolecules 2000; 33:9306-09.
32. Teng Y, Morrison ME, Munk P, Webber SE, Procháka K. Release kinetics studies of aromatic molecules into water block copolymer micelles. Macromolecules 1998; 31:3578-87.
33. Duncan R, Kopeček J. Soluble synthetic polymers as potential drug carriers. Adv Polym Sci 1984; 57:51-101.
34. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53:283-318.
35. Papisov MI. Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo). Adv Drug Deliv Rev 1995; 16:127-39.
36. Scholz C, Iijima M, Nagasaki Y, Kataoka K. A novel reactive polymeric micelle with aldehyde groups on its surface. Macromolecules 1995; 28:7295-97.
37. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA 2003; 100:6039-44.
38. Yokoyama M, Okano T. Targetable drug carriers: present status and future perspective. Adv Drug Deliv Rev 1996; 21:77-80.
39. Štěpánek M, Podhájecká K, Tesařová E, Procházka K, Tuzar Z, Brown W. Hybrid polymeric micelles with hydrophobic cores and mixed polyelectrolyte/nonelectrolyte shells in aqueous media. 1. Preparation and basic characterization. Langmuir 2001; 17:4240-44.
40. Nagarajan R, Barry M, Ruckenstein. Unusual selectivity in solubilization by block copolymer micelles. Langmuir 1986; 2:210-15.
41. Okazaki S, Nishiyama N, Kato Y, Sugiyama Y, Miyamoto M, Kataoka K. Enhanced tumor accumulation and anticancer activity of cisplatin-loaded polymeric micelles. J Control Release 2003; 91:233-36.
42. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of genes and related compounds. Adv Drug Deliv Rev 2002; 54:203-22.
43. Yu L, Kwon GS. Micelle-like structures of poly(ethylene oxide)-block-poly(2-hydroxyethyl aspartamide)-methotrexate conjugates. Colloids Surf B Biointerfac 1999; 16:217-26.
44. Bae YS, Fukushima S, Harada A, Kataoka K. Preparation and characterization of pH responsive adriamycin-loaded polymeric micelles: drug release profile an in vitro cytotoxicity of human lung cancer SBC-3. J Control Release 2003; 91:233-236.
45. Rodriguez SC and Singer EJ. Toxicology of polyoxyalkylene block copolymers. In: Nace VM, editor. Nonionic Surfactants. New York: Dekker, 1996.
46. Hunter RL, McNicholl J. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res Hum Retroviruses 1994; 10(Suppl 2):S95-S98.
47. Johnston TP, Miller SC. Toxicological evaluation of poloxamer vehicles for intramuscular use. Bull Parenteral Drug Assoc 1985; 39:83-9.
48. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002; 19:1-72.
49. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54:759-79.
50. Kabanov AV, Lemieux P, Vingradov S, Alakhov V. Pluronic block copolymers: novel functional molecules for gene delivery. Adv Drug Deliv Rev 2002; 54:223-33.
51. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Rev Cancer 2003; 3:50216.
52. Venne A, Li R, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of Pluronic 161 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multi drug-resistant cells. Cancer Res 1996; 56:3626-29.
53. Batrakova EV, Lee S, Li S, Venne A, Alakhov V, Kabanov A. Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effects in MDR cancer cells. Pharm Res 1999; 16:1373-79.
54. Alakhov VY, Moskaleva EY, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant ovarian carcinoma cells by Pluronic p85 block copolymer. Bioconjugate Chem 1996; 7:209-16.
55. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic p85 increases permeability of a broad spectrum of drugs in polarized bbmec and caco-2 monolayers. Pharm Res 1999; 16:1366-72.
56. Batrakova EV, Han HY, Alakhov V, Miller DW, Kabanov AV. Effects of Pluronic block copolymers on drug absorption in caco-2 monolayers. Pharm Res 1998; 15:850-55.
57. Batrakova EV, Miller DW, Li S, Alakhov Y, Kabanov AV, Elmquist WF. Pluronic p85 enhances the delivery of digoxin in the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296:551-7.
58. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. Optimal structural requirements for Pluronic block copolymers in modifying p-glycoprotein drug efflux activity in bovine brain endothelial cells. J Pharmacol Exp Ther 2003; 304:845-54.
59. Alakhov V, Klinski E, Li S, Pietrzynski G, Venne A, Batrakova E, Bronitch T, Kabanov A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surfaces B Biointerfac 1999; 16:113-34.
60. Ranson M, Ferry D, Kerr D, Radford J, Dickens D, Alakhov V, Brampton M, Margison J. Results of a cancer research campaign phase I dose escalation trial of sp1049c in patients with advanced cancer. 5th Int Symp Polym Ther 2002:15.
61. MacPherson RD. Pharmaceutics for the anesthetist. Anaesthesia 2001; 56:965-79.
62. Meadows J, Higginbottom S. Anaesthetic formulations of propofol. WO03/017977, 2003.
63. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9:499-511.
64. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000; 30:653-7.
65. Dupont B. Overview of the lipid formulations of amphotericin b. J Antimicrob Chemother 2002; 49:S31-6.
66. Bennett J. Choosing amphotericin b formulations-between a rock and a hard place. Clin Infect Dis 2000; 31:1164-5.
67. van Etten EWM, van Vianen W, Tijhuis RHG, Storm G, Bakker-Woudenberg IAJM. Sterically stabilized amphotericin B-liposomes: Toxicity and biodistribution in mice. J Control Release 1995; 37:123-29.
68. van Etten EWM, Ten Kate MT, Stearne LET, Bakker-Woudenberg IAJM. Amphotericin b liposomes with prolonged circulaton in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrob Agents Chemother 1995; 39:1954-58.
69. Otsubo T, Maruyama K, Maesaki S, Miyazaki Y, Tanaka E, Takizawa T, Moribe K, Tomono K, Tashiro T, Kohno S. Long-circulating immunoliposomal amphotericin b against invasive pulmonary aspergillosis in mice. Antimicrob Agents Chemother 1998; 42:40-4.
70. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin b. Clin Microbiol Rev 1996; 9:512-31.
71. Bolard J, Legrand P, Heitz F, Cybulska B. One-sided action of amphotericin b on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 1991; 30:5707-15.
72. Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin b on its toxicity to mice. Antimicrob Agents Chemother 1992; 36:2310-5.
73. Espuelas MS, Legrand P, Chron M, Barratt G, Puisieux F, Devissaguett JPh, Irache JM. Interaction of amphotericin b with polymeric colloids a spectroscopic study. Colloids Surf B Biointerfac 1998; 11:141-51.
74. Espuelas MS, Legrand P, Campanero MA, Applet M, Chéron M, Gamazo C, Barratt G, Irache JM. Polymeric carriers for amphotericin b: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 2003; In press.
75. Yu B, Nichols BC, Aramwit P, Kwon, G. The effect of Pluronics-f127 and f68 on the aggregation state and hemolytic activity of nystatin. In: Park KD, Kwon IC, Yui N, Jeong SY, Park K, editors. Biomaterials and Drug Delivery Toward a New Millenium. Seoul: Hanrimwon, 2000.
76. Hioka N, Chowdhary RK, Chansarkar N, Delmarre D, Sternberg E, Dolphin D. Studies of a benzoporphrin derivative with Pluronics. Can J Chem 2002; 80:1321-1326.
77. Vrouenraets MB, Visser GWM, Snow GB, van Dongen GAMS. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 2003; 23:505-22.
78. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide) -block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002; 54:169-90.
79. Deming TJ, Polypeptide materials: new synthetic methods and applications. Adv Mater 1997; 9:299-311.
80. Van Domeselaar GH, Kwon GS, Andrew LC, Wishart DS. Application of solid phase peptide synthesis to engineering peo-peptide block copolymers for drug delivery. Colloids Surf B Biointerfac 2003; 30:323-34.
81. Dorn K, Hoerpel G, Ringsdorf H. Polymeric anti-tumor agents on a molecular and cellular level. In: Gebelein CG, Carraher CE, editors. Bioactive Polymeric Systems. New York: Plenum, 1985.
82. Rihova B, Riha I. Immunological problems of polymer-bound drugs. CRC Crit Rev Ther Drug Carrier Syst 1985; 1:311-74.
83. Chiu HC, Kopečková P, Deshmane SS, Kopeček J. Lysosomal degradation of poly(α-amino acids). J Biomed Mat Res 1997; 34:38-92.
84. Teitelbaum D, Arnon R, Sela M. Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 1997; 53:24-8.
85. Daly WH, Poché D. The preparation of n-carboxyanhydrides of α-amino acids using bis(trichloromethyl)carbonate. Tetrahedron Lett 1988; 29:5859-62.
86. Yokoyama M, Miyauchi M, Yamada N, Okano T, Kataoka K, Inoue S. Polymeric micelles as novel drug carrier: adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. J Control Release 1990; 11:269-78.
87. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y. Polymeric micelles as novel drug carriers and virus mimicking vehicles. In: Kahovec J, editor. Macromolecules 1992. Zeist: VSP, 1993.
88. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Seto T, Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconjugate Chem 1992; 3:295-301.
89. Yokoyama M, Sugiyama T, Okano T, Sakurai Y, Naito M, Kataoka K. Analysis of micelle formation of an adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer by gel permeation chromatography. Pharm Res 1993; 10:895-99.
90. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 1991; 51:3229-36.
91. Kwon GS, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Biodistribution of micelle-forming polymer-drug conjugates. Pharm Res 1993; 10:970-74.
92. Kwon GS, Suwa S, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Release 1994; 29:17-23.
93. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kataoka K. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Targeting 1999; 7:171-86.
94. Kataoka K, Matsumoto T, Yokoyama, M, Okano T, Sakuri Y, Fukushima S, Okamoto K, Kwon GS. Doxorubicin-loaded poly(ethylene glycol)-poly(β -benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000; 64:143-53.
95. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K. Development of the polymeric micelle carrier system for doxorubicin. J Control Release 2001; 74:295-302.
96. Matsumura Y. Phase I clinical trial of NK911, polymer micelle encapsulated doxorubicin. Proc. Winter Symp & 11th Int Symp Recent Adv Drug Del Syst 2003; 55.
97. Kamishohara M, Kawai H, Sakai T, Isoe T, Hasegawa K, Mochizuki J, Uchida T, Kataoka S, Yamaki H, Tsuruo T, Otake N. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells. Oncol Res 1994; 6:383-90.
98. Yokoyama M, Satoh A, Sakurai Y, Okano T, Matsumura Y, Kakizoe T, Kataoka K. Incorporation of water-insoluble anticancer drug into polymeric micelles and control of their particle size. J Control Release 1998; 55:21929.
99. Mutsumura Y, Yokoyama M, Kataoka K, Okano T, Sakurai Y, Kawaguchi T, Kakizoe T. Reduction of the size effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res 1999; 90:122-28.
100. Mizumura M, Mutsumura Y, Yokoyama M, Okano T, Kawaguchi T, Moriyasu F, Kakizow T. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity. Jpn J Cancer Res 2002; 93:1237-43.
101. Yu BG, Okano T, Kataoka K, Kwon G. Polymeric micelles for drug delivery; solubilization and haemolytic activity of amphotericin b. J Control Release 1998; 53:131-36.
102. Lavasanifar A, Samuel J, Kwon GS. Micelles of poly(ethylene oxide)-block-poly(hydroxyethyl-L-aspartamide): synthetic analogues of lipoproteins for drug delivery. J Biomed Mat Res 2000; 52:831-35.
103. Lavasanifar A, Samuel J, Kwon GS. Micelles of poly(ethylene oxide)-block-poly(N-hexyl stearate L-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin b. J Control Release 2001; 77:155-60.
104. Lavasanifar A, Samuel J, Sattari S, Kwon GS. Block copolymer micelles for the encapsulation and delivery of amphotericin b. Pharm Res 2002; 19:418-22.
105. Feijen J, Gregonis D, Anderson C, Peterson RV, Anderson J. Coupling steroid hormones to biodegradable poly(alpha-amino acid)s. Part 1. Norethindrone coupled to poly-N5-(3-hydroxypropyl-L-glutamine). J Pharm Sci 1980; 69:871-2.
106. Lavasanifar A, Samuel J, Kwon GS. The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly(L-aspartamide) derivatives. Colloid Surf B Biointerfac 2001; 22:11526.
107. Adams ML, Kwon GS. The effects of acyl chain length on the micelle properties of poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugates. J Biomater Sci Polymer Ed 2002; 13:991-1006.
108. Lavasanifar A, Samuel J, Kwon GS. The effect of fatty acid substitution on the in vitro release of amphotericin b from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). J Control Release 2002; 79:165-72.
109. Adams ML, Kwon GS. Relative aggregation state and hemolytic activity of amphotericin b encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release 2003; 87:23-32.
110. Adams ML, Andes DR, Kwon GS. Amphotericin b encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules 2003; 4:750-57.
111. Liggins RT, Burt HM. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Delivery Rev 2002; 54:191-202.
112. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 2002; 82:17-27.
113. Ould-Ouali L, Rouxhet L, Langlois X, Brewster M, Préat V, Ariën A. Self-assembling diblock copolymer for oral drug delivery of a poorly water soluble drug: a pharmacokinetics and pharmacodynamics approach. Proc 30th Control Release Soc Ann Mtg 2003; 460.
114. Zastra J, Jackson J, Bajwa M, Liggins R, Burt H. Enhanced cellular accumulation of p-glycoprotein substrate, rhodamine-123, by caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers. Eur J Pharm Biopharm 2002; 54:299-309.
115. Savić R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003; 300:615-18.
116. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of Taxol. Int J Pharm 1998; 132:195-206.
117. Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. Development of copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Interfac B Biointerfac 1999; 16:161-71.
118. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modified surface charge. J Control Release 2001; 77:27-38.
119. Zhang X, Burt HM, Von Hoff D, Dexter, D, Mangold G, Degen D, Oktaba AM, Hunter WL. An investigation of the antitumor activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 1997; 40:81-6.
120. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001; 72:191-202.
121. Brahm E, Arsenault T, Cheng T, Banquerigo ML, Zhang X, Burt HM, Hunter. Micellar taxol and methotrexate in collagen-induced arthritis: suppression of synovial angiogenesis and regression of arthritis. Arthritis Rheum 1996; 39:S307.
122. Cao L, Sun D, Cruz T, Moscarello MA, Ludwin SK, Whitaker JN. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J Neuroimmunol 2000; 108:103-11.
123. Soo PL, Luo L, Maysinger D, Eisenberg. Incorporation and release of hydrophobic probes in biocompatible polycaprolactone-block-poly(ethylene oxide) micelles: implications for drug delivery. Langmuir 2002; 18:9996-10004.
124. Kohori F, Yokoyama M, Sakai K, Okano T. Process design for efficient and controlled drug incorporation into polymeric micelle carrier systems. J Control Release 2002; 78:155-63.
125. Trubetskoy VS, Torchilin VP. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Deliv Rev 1995; 16:311-20.
126. Lee MK, Choi L, Kim MH, Kim CK. Pharmacokinetics and organ distribution of cyclosporin a incorporated in liposomes and mixed micelles. Int J Pharm 1999; 191:87-93.
127. Gao Z, Luyanov AN, Singhai A, Torchilin VP. Diacyllipid-polymer micelles as nano-carriers for poorly soluble anticancer drugs. Nanoletters 2002; 2:979-82.
128. Krishnada A, Rubinstein I, Önyüksel, H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm Res 2003; 20:297-302.
129. Zhang JX, Hansen CB, Allen TM, Boey A, Boch R. Lipid-derivatized poly(ethylene glycol) micellar formulations of benzoporphyrin derivatives. J Control Release 2003; 86:323-38.